tbuckley/cabot-search huggingface dataset:
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Authors: Nitya Raj, Youyun Zheng, Virginia Kelly, Seth S. Katz, Joanne Chou, Richard K.G. Do, Marinela Capanu, Dmitriy Zamarin, Leonard B. Saltz, Charlotte E. Ariyan, Brian R. Untch, Eileen M. O'Reilly, Anuradha Gopalan, Michael F. Berger, Kelly Olino, Neil H. Segal, Diane L. Reidy-Lagunes
Journal: Journal of Clinical Oncology (2019)

Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity of ACC.Patients with advanced ACC were enrolled in a phase II study to evaluate the clinical activity of pembrolizumab 200 mg every 3 weeks, without restriction on prior therapy. The primary end point was objective response rate. Efficacy was correlated with tumor programmed death-ligand 1 expression, microsatellite-high and/or mismatch repair deficient (MSI-H/MMR-D) status, and somatic and germline genomic correlates.We enrolled 39 patients with advanced ACC and herein report after a median follow-up of 17.8 months (range, 5.4 months to 34.7 months). The objective response rate to pembrolizumab was 23% (nine patients; 95% CI, 11% to 39%), and the disease control rate was 52% (16 patients; 95% CI, 33% to 69%). The median duration of response was not reached (lower 95% CI, 4.1 months). Two of six patients with MSI-H/MMR-D tumors responded. The other seven patients with objective responses had microsatellite stable tumors. The median progression-free survival was 2.1 months (95% CI, 2.0 months to 10.7 months), and the median overall survival was 24.9 months (95% CI, 4.2 months to not reached). Thirteen percent of patients (n = 5) had treatment-related grade 3 or 4 adverse events. Tumor programmed death-ligand 1 expression and MSI-H/MMR-D status were not associated with objective response.MSI-H/MMR-D tumors, for which pembrolizumab is a standard therapy, are more common in ACC than has been recognized. In advanced ACC that is microsatellite stable, pembrolizumab provided clinically meaningful and durable antitumor activity with a manageable safety profile.
EP1.16-20 Pembrolizumab - Subsequent Lines in Non-Small Cell Lung Cancer: The Experience of a Tertiary Hospital
Authors: N. China Pereira, A. Mendes, D. Reis, M. Dias, D. Coutinho, T. Costa, E. Silva, S. Campainha, S. Conde, A. Barroso
Journal: Journal of Thoracic Oncology (2019)
P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
Authors: J.M. Trigo Perez, V. Subbiah, B. Besse, V. Moreno, R. López, M.a. Sala, S. Ponce, C. Fernendez, A. Nieto, C. Kahatt, A. Zeaiter, K. Zaman, V. Boni, J. Arrondeau, M. Martinez, J. Delord, A. Awada, R. Kristeleit, F. Longo, J. Sarantopoulos, M. Rubio, A. Anton, L. Wannesson, J. Valdivia, G. Shappiro, V. Villalobos, A. Santoro, M. D'Arcangelo, L. Aparicio, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2019)
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
Authors: A. Drilon, G. Oxnard, L. Wirth, B. Besse, O. Gautschi, S.W.D. Tan, H. Loong, T. Bauer, Y.J. Kim, A. Horiike, K. Park, M. Shah, C. McCoach, L. Bazhenova, T. Seto, M. Brose, N. Pennell, J. Weiss, I. Matos, N. Peled, B.C. Cho, Y. Ohe, K. Reckamp, V. Boni, M. Satouchi, G. Falchook, W. Akerley, H. Daga, T. Sakamoto, J. Patel, N. Lakhani, F. Barlesi, M. Burkard, V. Zhu, V. Moreno Garcia, J. Medioni, M. Matrana, C. Rolfo, D.H. Lee, H. Nechushtan, M. Johnson, V. Velcheti, M. Nishio, R. Toyozawa, K. Ohashi, L. Song, J. Han, A. Spira, F. De Braud, K. Staal Rohrberg, S. Takeuchi, J. Sakakibara, S. Waqar, H. Kenmotsu, F. Wilson, None B.Nair, E. Olek, J. Kherani, K. Ebata, E. Zhu, M. Nguyen, L. Yang, X. Huang, S. Cruickshank, S. Rothenberg, B. Solomon, K. Goto, V. Subbiah
Journal: Journal of Thoracic Oncology (2019)
Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death
Authors: Susanna F. Fustolo-Gunnink, Karin Fijnvandraat, David van Klaveren, Simon J. Stanworth, Anna Curley, Wes Onland, Ewout W. Steyerberg, Ellen de Kort, Esther J. d’Haens, Christian V. Hulzebos, Elise J. Huisman, Willem P. de Boode, Enrico Lopriore, Johanna G. van der Bom
Journal: Blood (2019)
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with thymic carcinoma. We sought to evaluate the efficacy and safety of the anti-PD-L1 antibody, avelumab (MSB0010718C), in patients with relapsed, advanced thymic epithelial tumors and conduct correlative immunological studies. <h3>Methods</h3> Seven patients with thymoma and one patient with thymic carcinoma were enrolled in a phase I, dose-escalation trial of avelumab (MSB0010718C), and treated with avelumab at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or development of intolerable side effects. Tissue and blood immunological analyses were conducted. <h3>Results</h3> Two of seven (29%) patients with thymoma had a confirmed Response Evaluation Criteria in Solid Tumors–defined partial response, two (29%) had an unconfirmed partial response and three patients (two thymoma; one thymic carcinoma) had stable disease (43%). Three of four responses were observed after a single dose of avelumab. All responders developed immune-related adverse events that resolved with immunosuppressive therapy. Only one of four patients without a clinical response developed immune-related adverse events. Responders had a higher absolute lymphocyte count, lower frequencies of B cells, regulatory T cells, conventional dendritic cells, and natural killer cells prior to therapy. <h3>Conclusion</h3> These results demonstrate anti-tumor activity of PD-L1 inhibition in patients with relapsed thymoma accompanied by a high frequency of immune-related adverse events. Pre-treatment immune cell subset populations differ between responders and non-responders. <h3>Trial registration</h3> ClinicalTrials.gov - NCT01772004. Date of registration – January 21, 2013.
Syria: MSF evacuates staff amid “extreme volatility” from Turkish offensive
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The humanitarian aid agency Medecins Sans Frontieres (MSF) has taken the “difficult decision” to suspend most of its activities in northeast Syria, where it has been providing food, water, and medical assistance, because of the volatile situation caused by Turkish military operations in the area.

Save the Children has also had to evacuate international staff, although local workers, who make up most of the workforce in the area, are continuing to provide services where possible.

Northeast Syria, which borders Turkey, is the largest area not controlled by Syrian president Bashar al-Assad or his allies. Before the Turkish government offensive, which started on 9 October, it was controlled by the Syrian …
P1.14-07 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance
Authors: E. Stewart, A. Wang, J. Huang, H. Bao, X. Wu, D. Patel, Z. Chen, J. Law, P. Bradbury, F. Shepherd, A. Sacher, M. Tsao, S. Bratman, N. Leighl, T. Pugh, G. Liu
Journal: Journal of Thoracic Oncology (2019)
Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial)
Authors: Sherrill J. Slichter, Richard M. Kaufman, Susan F Assmann, Mark E. Brecher, Terry Gernsheimer, Christopher D. Hillyer, Jeffrey McCullough, Ronald G. Strauss, Darrell Triulzi
Journal: Blood (2008)
Frequency of Heparin-Induced Thrombocytopenia and Heparin-Dependent IgG Antibodies in Hematopoietic Stem Cell Transplant Recipients.
Authors: Michelle A. Elliott, Sandra Schulte, Elizabeth A. Plumhoff, Rajiv K. Pruthi, William L. Nichols, Mark R. Litzow, Dennis A. Gastineau, John A. Heit
Journal: Blood (2006)
EP1.04-05 Outcomes of Immunotherapy in Elderly Patients. Retrospective Study of Clinical Characteristics in a Single-Center and a 4-Year Experience
Authors: A.L. Ortega Granados, D. Fernández Garay, N. Cárdenas Quesada, J.F. Marín Pozo, L. Díaz Beltrán, C. De La Torre Cabrera, M. Ruiz Sanjuan, M. Fernández Navarro, M.Á. Moreno Jiménez, P. Sánchez Rovira
Journal: Journal of Thoracic Oncology (2019)
P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001
Authors: P. Rochigneux, A. Lisberg, A. Garcia, A.S. Chretien, S. Fattori, A. Madroszyk, A. Tseng, W. Akingbemi, J. Gukasyan, J. Madrigal, J. Carroll, Z. Noor, A. Cummings, D. Olive, E. Garon
Journal: Journal of Thoracic Oncology (2019)
MA15.10 Stromal Markers of Activated Tumor Associated Fibroblasts Predict Poor Survival and Are Associated with Necrosis in Non-Small Cell Lung Cancer
Authors: J. Alcaraz, J.L. Carrasco, M. Laura, A. Martínez-Romero, J. Sánchez De Cos, R. Rami-Porta, L.M. Seijo, J. Ramirez, N. Reguart, E. Barreiro, E. Monsó
Journal: Journal of Thoracic Oncology (2019)
P2.01-26 EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
Authors: M. Gogishvili, N. Mobashery, T. Makharadze, M. Navarro, P. Snodgrass, H. Chen, I. Lowy, P. Rietschel, S. Lee
Journal: Journal of Thoracic Oncology (2019)
Respiratory Syncytial Virus Disease Severity Is Associated with Distinct CD8<sup>+</sup> T-Cell Profiles
Authors: David T. Siefker, Luan Vu, Dahui You, Andrew McBride, Ryleigh Taylor, Tamekia L. Jones, John DeVincenzo, Stephania A. Cormier
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Rationale: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Although T-helper type 2 (Th2) cell pathology is implicated in severe disease, the mechanisms underlying the development of immunopathology are incompletely understood.Objectives: We aimed to identify local immune responses associated with severe RSV in infants. Our hypothesis was that disease severity would correlate with enhanced Th2 cellular responses.Methods: Nasal aspirates were collected from infants hospitalized with severe (admitted to the pediatric ICU) or moderate (maintained in the general ward) RSV disease at 5 to 9 days after enrollment. The immune response was investigated by evaluating T-lymphocyte cellularity, cytokine concentration, and viral load.Measurements and Main Results: Patients with severe disease had increased proportions of CD8 (cluster of differentiation 8)-positive T cells expressing IL-4 (Tc2) and reduced proportions of CD8+ T cells expressing IFNγ (Tc1). Nasal aspirates from patients with severe disease had reduced concentrations of IL-17. Patients with greater frequencies of Tc1, CD8+ T cells expressing IL-17 (Tc17), and CD4+ T cells expressing IL-17 (Th17) had shorter durations of hospitalization.Conclusions: Severe RSV disease was associated with distinct T-cell profiles. Tc1, Tc17, and Th17 were associated with shorter hospital stay and may play a protective role, whereas Tc2 cells may play a previously underappreciated role in pathology.
Hereditary Thrombotic Thrombocytopenic Purpura
Authors: Johanna A. Kremer Hovinga, James N. George
Journal: New England Journal of Medicine (2019)

Hereditary thrombotic thrombocytopenic purpura is an autosomal recessive disorder caused by the absence of a functional protease (ADAMTS13) that processes von Willebrand factor multimers into smaller fragments. The multimers bind to platelets and initiate abnormal clotting, thrombosis, and hemolysis.
P1.01-134 SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
Authors: M. Ahn, M. Cantarini, P. Frewer, G. Hawkins, J. Peters, P. Howarth, G. Ahmed, T. Sahota, R. Hartmaier, X. Li-Sucholeiki, G. Oxnard
Journal: Journal of Thoracic Oncology (2019)
OA09.01 Opt-Out Smoking Cessation Program in Lung Cancer Screening Provides Excellent Quit Rates
Authors: R. Myers, S. Atkar-Khattra, S. Pillainayagam, S. Ladhar, K. Cho, M. Janicker, J. Callaghan, J. Yee, S. Lam
Journal: Journal of Thoracic Oncology (2019)
P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1
Authors: E. Redin, M. Villalba, F. Exposito, M.J. Pajares, C. Sainz, D. Hervas, E. Guruceaga, A. Diaz-Lagares, C. Cirauqui, M. Redrado, C. De Andrea, E. Jantus, C. Camps, R. López, A. Lahoz, L. Montuenga, R. Pio, J. Sandoval, A. Calvo
Journal: Journal of Thoracic Oncology (2019)
P2.18-11 Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: A. Barbaro, F. Mienko, L. Deng, N. Ohri, B. Halmos, R. Perez-Soler, R. Gucalp, W. Bodner, H. Cheng
Journal: Journal of Thoracic Oncology (2019)
P2.03-54 Imprinted Genes Predict Non-Small Cell Lung Cancer Prognosis
Authors: J. Zhou, T. Cheng, X. Li, X. Wang, H. Si, P. Zhao, R. Yung, R. Shen, H. Yu, S. Lu, W. Huang, N. Zhou, C. Bai
Journal: Journal of Thoracic Oncology (2019)
Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Authors: Gary D. Lewis, Yan Xing, Waqar Haque, Tejal Patel, Mary Schwartz, Albert Chen, Andrew Farach, Sandra S. Hatch, E. Brian Butler, Jenny Chang, Bin S. Teh
Journal: Cancer Communications (2019)

Invasive micropapillary carcinoma (IMPC) is an uncommon subtype of breast cancer. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases as compared with invasive ductal carcinoma (IDC). The purpose of the present study was to determine the clinical characteristics, outcomes, and propensity for lymph node metastasis of patients with IMPC of the breast recorded in the National Cancer Database (NCDB).Records of patients with IMPC diagnosed between 2004 and 2014 were retrieved from the NCDB. Log-rank test was performed to evaluate associations of clinical characteristics with overall survival (OS). Cox proportional hazards model was used to determine variables associated with OS.Overall, 2660 patients with IMPC met the selection criteria; the 5-year OS rate was 87.5% and 24.9% of patients had nodal involvement at presentation. Patients with ≥ 4 positive lymph nodes had shorter OS than node-negative patients, whereas patients with 1-3 positive nodes had similar OS to node-negative patients. Age < 65 years, receipt of radiotherapy, and estrogen receptor positivity were also associated with prolonged OS. The benefit of radiotherapy was limited to IMPC patients undergoing lumpectomy; there was no benefit for the patients undergoing mastectomy (regardless of nodal positivity/negativity).Favorable prognostic factors of IMPC patients included age < 65 years, < 4 positive lymph nodes, receipt of radiotherapy, and estrogen receptor positivity. The results presented herein suggest a survival benefit associated with radiotherapy in IMPC treatment, though this may be limited to the patients treated with lumpectomy.
Unique subpopulations of cord blood innate lymphoid cells are associated with lung function at 6 weeks of age in babies born to mothers with asthma during pregnancy
Authors: G. M. C. Gomes, P. G. Belinelo, M. R. Starkey, K. Jesson, S. Loering, P. M. Hansbro, V. E. Murphy, K. Hardaker, P. D. Robinson, P. D. Sly, P. G. Gibson, J. Mattes, A. M. Collison
Journal: Allergy (2019)
Real-Time Benefit Tools for Drug Prices
Authors: Jordan Everson, Mark E. Frisse, Stacie B. Dusetzina
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P2.03-15 Validation of Tumor Organoids from Lung Adenocarcinoma as a Model of Primary Tumor Genotype
Authors: C. Seder, A. Arndt, J. Karush, N. Geissen, C. Wakefield, A. Naqib, M. Liptay, C. Frankenberger, J. Borgia
Journal: Journal of Thoracic Oncology (2019)
IR-003. CCR4+ REGULATORY T CELLS ACCUMULATE WITHIN THE BRAIN TUMOR IN AN EXPERIMENTAL MODEL OF GBM
Authors: Alan Chang, Derek Wainwright, Mahua Dey, Yu Han, Maciej Lesniak
Journal: Neuro-Oncology (2013)

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. One hallmark of GBM is the accumulation of infiltrating regulatory T cells (Tregs), a highly immunosuppressive T cell subset that suppresses T cell-mediated GBM rejection. Previous work has demonstrated that th
Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis
Authors: Kapil Kohli, Ajoy L. Dias, Neil Dunavin, Leyla Shune, Tara L. Lin, Sunil Abhyankar, Anurag K. Singh, Siddhartha Ganguly, Joseph P. McGuirk, Barry S. Skikne
Journal: Blood (2017)
EP1.17-21 Early Stage NSCLC (ES-NSCLC) 5-Fraction Stereotactic Body Radiation Therapy (SBRT) 3-Year Patterns of Failure
Authors: R. Krochmal, N. Aghdam, S. Kataria, M. Pernia, C. Hall, T. O’Connor, L. Campbell, S. Suy, S. Collins, J. Lischalk, E. Anderson, B. Collins
Journal: Journal of Thoracic Oncology (2019)
Case 33-2019: A 35-Year-Old Woman with Cardiopulmonary Arrest during Cesarean Section
Authors: Sarah N. Bernstein, Gaston A. Cudemus-Deseda, Vilma E. Ortiz, Annekathryn Goodman, Arminder S. Jassar
Journal: New England Journal of Medicine (2019)

A 35-year-old pregnant woman was admitted to the hospital for cesarean section because of placenta previa. Within minutes after delivery, the patient had sudden cardiovascular collapse, followed by disseminated intravascular coagulation. A diagnosis and management decisions were made.
P2.03-51 Gene Variants and Expressions of Galectin-3 Is Associated with Non Small Cell Lung Cancer and Vascular Invasion of the Tumor
Authors: S. Terzioglu Usak, S. Demirkol, C. Horozoglu, D. Sönmez, İ. Yaylım, A. Turna
Journal: Journal of Thoracic Oncology (2019)
EP1.16-44 Survival and Prognostic Association of Non-Small Cell Lung Cancer with Brain Metastases After WBRT: A Multicentre Study
Authors: M. Shuayb, M.S.J.R. Shahi, M.S. Reza, A.M.M. Shariful Alam, X. Dong
Journal: Journal of Thoracic Oncology (2019)
MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer
Authors: S. Ortiz-Cuaran, L. Mezquita, A. Swalduz, M. Aldea, J. Mazieres, C. Jovelet, W.R. Chumbi Flores, L. Lacroix, Y. Loriot, L. Friboulet, V. Westeel, M. Ngocamus, A. Pradines, C. Tissot, C. Clement Duchene, C. Raynaud, X. Quantin, R. Gervais, E. Brain, I. Monnet, E. Giroux Leprieur, V. Avrillon, C. Mahier-Aït Oukhatar, N. Hoog-Labouret, F. De Kievit, K. Howarth, J. Guichou, C. Morris, E. Green, M. Perol, B. Besse, J. Blay, P. Saintigny, D. Planchard
Journal: Journal of Thoracic Oncology (2019)
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency
Authors: Robert A. Brodsky
Journal: Journal of Clinical Investigation (2019)

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by hemolysis, thrombosis, and bone marrow failure caused by defective expression of glycosylphosphatidylinositol-anchored (GPI-anchored) complement inhibitors. Most commonly, PNH is caused by loss of function of PIGA, which is required for GPI biosynthesis. In this issue of the JCI, Höchsmann et al. report on 4 PNH patients who also had marked autoinflammatory manifestations, including aseptic meningitis. All 4 patients had a germline mutation of the related gene PIGT and a somatically acquired myeloid common deleted region (CDR) on chromosome 20q that deleted the second PIGT allele. The biochemistry and clinical manifestations indicate that these patients have subtle but important differences from those with PNH resulting from PIGA mutations, suggesting PIGT-PNH may be a distinct clinical entity.
EP1.15-13 Prognosis of Colorectal Cancer Cases That Underwent Lung and Liver Metastasectomy and Therapeutic Outcomes of Brain Metastasis
Authors: T. Fujita, M. Kataoka, K. Suemori, D. Okutani, K. Watanabe, H. Kawai, S. Harita
Journal: Journal of Thoracic Oncology (2019)
P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
Authors: C. Aguado, C. Teixido, A. Gimenez-Capitan, E. Marin, A. Peréz-Rosado, C. Cabrera, R. Román, I. Moya, S. Viteri, R. Rosell, M.A. Molina-Vila, N. Reguart
Journal: Journal of Thoracic Oncology (2019)
Abortion in Northern Ireland is decriminalised
Authors: Clare Dyer
Journal: BMJ (2019)

Abortion in Northern Ireland has been decriminalised from 22 October after the UK parliament stepped in to liberalise a law that was among the most restrictive in Europe.

Abortion is an issue that is devolved to the Northern Ireland assembly at Stormont, but the assembly has not sat for nearly three years since the power sharing arrangement between the Democratic Unionist Party and Sinn Fein collapsed.

MPs in the UK parliament at Westminster voted overwhelmingly for the change last July after Stella Creasy, a Labour MP, put down an amendment to the Northern Ireland (Executive Formation etc) Bill, a technical bill connected to budgets and elections. It provided for the new law to come into effect immediately if the Northern …
P1.17-41 Preoperative Prognostic Nutritional Index (PNI) as a Prognostic Factor in Patients with Clinical Stage I Non-Small-Cell Lung Cancer
Authors: M. Matsumoto, K. Hagiwara, H. Komuro, Y. Miyamoto, H. Yamamoto, K. Shirahashi, K. Doi, H. Iwata
Journal: Journal of Thoracic Oncology (2019)
EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors
Authors: C.K. Liam, C.S. Chai, M.E. Poh, D.B.L. Ong, P.L. Cheah, Y.K. Pang, G.F. Ho, A. Alip
Journal: Journal of Thoracic Oncology (2019)
MA12.02 Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years
Authors: Y.Z. Zhang, C. Brambilla, A. Rice, J. Robertus, S. Jordan, E. Lim, L. Lang-Lazdunski, S. Popat, M. Moffatt, W. Cookson, A. Nicholson
Journal: Journal of Thoracic Oncology (2019)
P2.17-34 Integrated Clinico-Radiomic Nomogram for Predicting Disease-Free Survival (DFS) in Stage I and II Non-Small Cell Lung Cancer
Authors: K. Bera, P. Vaidya, P. Velu, H. Choi, P. Fu, A. Gupta, V. Velcheti, A. Madabhushi
Journal: Journal of Thoracic Oncology (2019)